Diacron reactive oxygen metabolites and biological antioxidant potential tests for patients with age-related macular degeneration

• Published in: BMC ophthalmology Vol. 20; no. 1; pp. 56 - 7
• Main Authors: Matsuura, Toshiyuki, Kaneko, Hiroki, Takayama, Kei, Shibata, Rei, Kataoka, Keiko, Ito, Seina, Tsunekawa, Taichi, Shimizu, Hideyuki, Suzumura, Ayana, Namba, Rina, Ito, Yasuki, Murohara, Toyoaki, Terasaki, Hiroko
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 18.02.2020; BioMed Central; BMC
• Subjects: Age; Age-related macular degeneration; Aged; Aged, 80 and over; Antioxidants; Antioxidants (Nutrients); Antioxidants - metabolism; Biological antioxidant potential; Biomarkers - blood; Care and treatment; Choroidal neovascularization; Choroidal Neovascularization - blood; Choroidal Neovascularization - diagnosis; Diacron reactive oxygen metabolites; Female; Fluorescein Angiography; Free radicals; Gender differences; Humans; Hypertension; Macular degeneration; Male; Male identity; Malondialdehyde; Metabolites; Middle Aged; Neovascularization; Oxidative Stress; Pathogenesis; Physiological aspects; Reactive Oxygen Species - blood; Statistical analysis; Visual Acuity - physiology; Wet Macular Degeneration - blood; Wet Macular Degeneration - diagnosis; Biological antioxidant potential; Oxidative stress; Choroidal neovascularization; Age-related macular degeneration; Diacron reactive oxygen metabolites
• ISSN: 1471-2415; 1471-2415
• DOI: 10.1186/s12886-020-01334-y

Previously, we showed that serum malondialdehyde (MDA) was significantly higher in patients with neovascular age-related macular degeneration (nAMD) than in those without AMD. The Diacron reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP) tests are known markers of oxidative stress. The aim of this study was to use d-ROMs and BAP tests to evaluate changes in systemic oxidative stress in patients with nAMD. Blood serum samples were collected from 34 patients with nAMD (mean age: 76.5 ± 7.7 years; 22 men) and 20 control subjects (mean age: 62.9 ± 14.0 years; 10 men), and d-ROMs and BAP tests were examined. In men, the mean level of d-ROMs for the nAMD patients was significantly higher than that for the controls (312.0 ± 52.4 vs. 275.1 ± 45.5 U.CARR, respectively; P < .05). There was a significant correlation between d-ROM level and CNV lesion area in the male nAMD group (r = .42, P = .05). There were no significant differences in mean BAP test results between the nAMD patients and controls for either sex (men: 2241 ± 549 vs. 2136 ± 246 μmol/L; women: 2263 ± 292 vs. 2335 ± 161 μmol/L). The d-ROMs test may provide a useful indicator of nAMD in men but not in women.